|
Poly swap, infection.The poly component was implanted for an unknown amount of time so simulated use testing would not be able to accurately recreate the physiological changes that occurred during implantation.There were 46 similar complaints identified for star poly swaps with no indication of poly damage.Similar complaints identified do not aid in the investigation for this complaint as the part and lot numbers remain unknown for the similar complaints.Ohr review was not conducted due to the lot number remaining unknown.It is unknown if the doctor followed the surgical technique with the limited information available regarding the original implantation.The poly was not returned to the houston site, so visual and dimensional inspection did not occur.Simulated use testing did not occur.The reporter stated the patient "began to form cysts on (their) tibia and talus near the implant site.The existing poly was a 7mm and replaced with a new 7mm.(the surgeon) removed the cysts and filled with calcium phosphate cement.The explant poly was not able to be retrieved.However, it did show sign of oxidization on the top of the implant".As the poly was not returned and there were no photographs provided of the poly, the amount of wear and potential oxidation could not be confirmed.Thus, the root cause shall remain as unknown.The following information remains unknown: date implanted.Patient height, weight, date of birth, bone quality, activity level, noncompliance, and co-morbidities.Inventory type.Lot number.Inventory status.Lnforrmation not provided is not available to the reporter.Thus, good faith effort was achieved.The overall risk is high with a risk index of 3.Severity level of 4 (significant) is appropriate as there could be permanent functional impairment of body function and the failure may occur with or without warning.It is to be noted that no adverse events were reported resulting from the swapped poly.It was determined that 696 polymer components (pn:400-14x) were sold january 2023 and january 2024.With 47 reported events, the occurrence rate is 6.75%.Thus, an occurrence level of 5 (frequenuhigh) is appropriate.Per rf-str-0001 revision 3 risk benefit analysis for u23.2, "every endoprosthesis has a limited lifespan.With state of the art techniques, there is no potential for further mitigation of the risks from a clinical point of view".Therefore, the risk shall remain appropriate.Though the root cause remains unknown it is not expected to be attributed to the supplier.
|